A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.
Metastatic Breast Cancer
DRUG: LY3295668 Erbumine|DRUG: Endocrine therapy|DRUG: Midazolam
Number of Participants with Dose Reductions, Number of Participants with Dose Reductions, Baseline through Cycle 1 (28 Day Cycle)|Part II: Number of Participants with Dose Limiting Toxicities (DLTs), Part II: Number of Participants with DLTs, Baseline through Cycle 1 (28 Day Cycle)|Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR), ORR, Baseline through Measured Progressive Disease (Estimated up to 23 Months)|Duration of Response (DoR), DoR, Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 23 Months)
Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR or SD With a Duration of At Least 6 Months, CBR, Baseline through Disease Progression or Death Due to Any Cause (Estimated up to 23 Months)|Progression-Free Survival (PFS), PFS, Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 23 Months)|Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3295668, PK: AUC of LY3295668, Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)|PK: AUC of LY3295668 in Combination with Endocrine Therapy, PK: AUC of LY3295668 in Combination with Endocrine Therapy, Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)|PK: AUC of Endocrine Therapy in Combination with LY3295668, PK: AUC of Endocrine Therapy in Combination with LY3295668, Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)|PK: AUC of Midazolam, PK: AUC of Midazolam, Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)|PK: AUC of Midazolam in Combination with LY3295668, PK: AUC of Midazolam in Combination with LY3295668, Predose Cycle 1 Day 1 through Cycle 2 Day 1 (28 Day Cycles)
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.